What are you looking for?

π-Alpha 293 AAV High-yield Production Platform

PackGene's proprietary π-Alpha 293 AAV High-Yield Platform represents a significant advancement in Adeno-Associated Virus (AAV) production and quality. The platform integrates an optimized PCS3.0 suspension cell line and a uniquely engineered RC plasmid within a triple-plasmid transfection system, achieving a 3 to 8-fold increase in AAV production across diverse serotypes. This foundational enhancement, coupled with rigorous Quality by Design (QbD) optimizations throughout both upstream and downstream processes, culminates in up to a 10-fold overall yield improvement. The platform consistently delivers single-batch yields reaching 1E+17 vg, effectively meeting the demands of clinical and commercial-scale AAV production.

GMP facility

Key Advantages

Enhanced Productivity and Scalability

Proprietary technologies drive a greater than 10-fold increase in AAV yield within HEK293 serum-free cell suspension systems.
Superior Purity

Refined process development significantly reduces key impurities, including Host Cell DNA (HCD) and endotoxin.
Improved Safety and Bioactivity

Innovative technological advancements minimize empty capsid and maximize infection titers.

Performance

Enhanced Productivity and Scalability

The PCS3.0 suspension cell line, combined with a uniquely engineered RC plasmid, enhances AAV production efficiency. This optimized system enables greater scalability for large-scale manufacturing.

Fig 1. PackGene’s proprietary RC plasmid significantly increases AAV production yield
Superior Purity

The optimized production process not only increases AAV yields but also significantly reduces the impurities.
Improved safety and bioactivity

The PackGene’s RC plasmid enhances full/empty capsid ratio to improve safety and bioactivity.

Resource

PackGene’s new GMP AAV manufacturing site-Houston, TX

Related Service

Download